Please login to the form below

Not currently logged in
Email:
Password:

FDA panel backs OTC use of Sanofi's allergy drug

Says Nasacort AQ can be sold without prescription

Sanofi reception

Sanofi is on course to win US approval for the over-the-counter (OTC) use of its allergy drug Nasacort AQ.

An advisory panel to the US Food and Drug Administration (FDA) voted 10 to six in favour of the indication, which would allow patients to buy Nasacort AQ (triamcinolone) without a prescription.

If given final approval by the FDA, the nasal spray would be the first medicine of its kind available as on OTC product.

It would be marketed by Sanofi's consumer healthcare division Chattem, which Sanofi acquired for just under $2bn in 2009.

“Today's positive Nonprescription Drugs Advisory Committee vote was an important step forward in providing broader access to Nasacort AQ for nasal allergy sufferers,” said Charles Hugh-Jones, chief medical officer, Sanofi US.

Nasacort AQ has been available as a prescription medicine for temporary relief of the symptoms of respiratory allergies for some time, making $375m at peak annual revenues.

Profits have declined since 2008, however, when Teva and Barr Pharmaceuticals won a patient challenge to launch their own generic copy, and Nasacort AQ achieved revenues of just €71m during 2012 for Sanofi.

The company will be hoping an OTC indication in the US will give it some advantage over the generic competition and boost sales.

This is part of a wider plan to build its consumer healthcare business, which CEO Chris Viehbacher discussed in the company's financial results for the second quarter of 2012.

Sanofi has already won OTC approval for another allergy drug, with Allegra (fexofenadine) backed by the FDA for non-prescription use in 2011 following the loss of patent exclusivity.

Allegra made €164m in the first half of 2013, becoming Sanofi's biggest selling consumer healthcare product, while prescription sales of the drug in the same period were down 6.8 per cent on 2012, coming in at €248m.

2nd August 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....